mefatinib
1 abstract
Abstract
Mefatinib as first-line treatment of EGFR sensitizing mutation-positive non-small-cell lung cancer: A phase III efficacy and biomarker study.Org: Huadong Medicine Co., Ltd, Huadong Global Development Center, HangZhou ZhongMei HuaDong Pharmaceutical Company,